CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Pulik Richard CFO | Sale | −45,195 | $41.47 | $1.9M | 351,851 |
| 2026-11-11 | Pulik Richard CFO | Sale | −82,170 | $42.03 | $3.5M | 269,681 |
| 2026-11-11 | Pulik Richard CFO | Sale | −47,635 | $41.89 | $2.0M | 222,046 |
| 2026-11-10 | Pulik Richard CFO | Sale | −125,000 | $41.20 | $5.2M | 269,681 |
| 2026-11-10 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −158,194 | $40.44 | $6.4M | 840,960 |
| 2026-11-10 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −29,749 | $41.00 | $1.2M | 811,211 |
| 2026-11-03 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.31 | $7.3M | 999,154 |
| 2026-10-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.59 | $7.3M | 1,199,154 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −185,856 | $35.09 | $6.5M | 1,413,298 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −14,144 | $35.42 | $501K | 1,399,154 |
| 2026-10-01 | Epperly Melissa B, Director | Sale 10b5-1 | −16,850 | $36.08 | $608K | 15,854 |
| 2026-10-01 | Epperly Melissa B, Director | Sale 10b5-1 | −900 | $36.57 | $33K | 14,954 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.62 | $7.3M | 1,599,154 |
| 2026-09-15 | Epperly Melissa B, Director | Sale 10b5-1 | −4,338 | $39.65 | $172K | 10,500 |
| 2026-09-15 | Epperly Melissa B, Director | Sale 10b5-1 | −600 | $40.38 | $24K | 9,900 |
| 2026-09-15 | Fitzgerald Meghan Director | Sale 10b5-1 | −4,712 | $39.68 | $187K | 36,508 |
| 2026-09-15 | Fitzgerald Meghan Director | Sale 10b5-1 | −400 | $40.45 | $16K | 36,108 |
| 2026-09-08 | Fitzgerald Meghan Director | Sale 10b5-1 | −20,000 | $39.90 | $798K | 42,963 |
| 2026-08-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −166,182 | $35.63 | $5.9M | 1,632,972 |
| 2026-08-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −33,818 | $36.44 | $1.2M | 1,599,154 |
Page 1 of 9 · 180 trades